Axcella Health Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Craig Jalbert

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	1.2yrs
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

Axcella decides not to expand enrollment in AXA4010-001 following cohort 1 readout

Jan 11

Is Axcella Health Inc.'s (NASDAQ:AXLA) Shareholder Ownership Skewed Towards Insiders?

Dec 28

CEO

Craig Jalbert (61 yo)

less than a year

Permanencia

Mr. Craig R. Jalbert, CIRA, serves as President, Corporate Secretary, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer at Evelo Biosciences, Inc. since November 21,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Craig Jalbert	President	less than a year	sin datos	sin datos
Alison Schecter	President of Strategy & Operations	no data	US$1.92m	0% $ 0
David Epstein	Consultant	1.2yrs	US$813.63k	0.22% $ 2.9k
Dan Kirby	Senior Vice President of Strategic Operations	1.6yrs	sin datos	sin datos
Marie Washburn	VP of Finance & Corporate Controller	no data	sin datos	sin datos
Karim Azer	Vice President of Platform & Discovery	no data	sin datos	sin datos

1.2yrs

Permanencia media

61yo

Promedio de edad

Equipo directivo experimentado: AXLAEl equipo directivo de la empresa no se considera experimentado ( 1.2 años de permanencia media), lo que sugiere un nuevo equipo.

Axcella Health Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Axcella Health Inc., Annual General Meeting, Sep 11, 2023

High number of new directors

High number of new directors

Axcella Health Inc. Announces Board Changes

Axcella Health Inc. Announces Management Changes

Axcella Health Inc., Annual General Meeting, May 19, 2022

Recent updates

The Nasdaq Stock Market to Delist the Common Stock of Axcella Health

Axcella Health Inc. Receives Non-Compliance Notice from Listing Qualifications Department of the Nasdaq Stock Market LLC

The Listing Qualifications Department of The Nasdaq Stock Market LLC Expresses Concerns Relating to Axcella Health's Non-Compliance with All Requirements for Continued Listing on the Nasdaq

Axcella Health Receives Non-Compliance Notice from Nasdaq

New major risk - Market cap size

Axcella Health Inc., Annual General Meeting, Sep 11, 2023

New major risk - Negative shareholders equity

Axcella Health Receives Non-Compliance Notice from Nasdaq Regarding Bid Price Requirement

Axcella Therapeutics Announces FDA IND Clearance for Supporting Regulatory Path to Registration of AXA1125

Axcella Therapeutics Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

Axcella Health Receives a Letter from the Listing Qualifications Department of Nasdaq

High number of new directors

High number of new directors

Axcella Health Inc. to Report Q3, 2022 Results on Nov 01, 2022

Price target decreased to US$8.83

Axcella Health Inc. Announces Board Changes

Axcella Therapeutics drops 9% on $34.2M stock offering

Axcella Health Inc. Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis

Axcella adds 20% as mid-stage trial indicates potential of NASH therapy

Axcella Health GAAP EPS of -$0.40 misses by $0.02

Price target decreased to US$9.67

Axcella Therapeutics Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID

Axcella Health Inc.(NasdaqGM:AXLA) dropped from Russell Microcap Value Index

Axcella Health Inc. Announces Management Changes

Price target decreased to US$11.00

Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio

Price target decreased to US$12.33

Axcella Health: Revisiting A Lottery Ticket

Axcella Health Inc., Annual General Meeting, May 19, 2022

Price target decreased to US$12.50

Price target increased to US$15.71

Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH

Axcella Therapeutics Announces Appointment of Robert Crane as the New Chief Financial Officer

Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial

Price target decreased to US$13.67

High number of new directors

Price target decreased to US$14.88

Axcella Announces Initiation of EMMPOWER Phase 2 Clinical Trial of AXA1665

Axcella Health Inc.(NasdaqGM:AXLA) dropped from Russell 3000E Value Index

Axcella Announces Positive Data from the AXA1665-002 Clinical

Axcella Health Inc. Announces Initiation of Emmpactsm Phase 2B Clinical Trial of Axa1125

Axcella Health EPS beats by $0.01

Axcella Health Inc. to Report Q4, 2020 Results on Mar 17, 2021

Executive VP of Clinical Development & Chief Medical Officer has left the company

Axcella Health Inc. Announces Executive Changes

Have Insiders Been Buying Axcella Health Inc. (NASDAQ:AXLA) Shares This Year?

New 90-day high: US$6.72

Insider exercised options and sold US$102k worth of stock

New 90-day high: US$5.99

Axcella Announces IND Clearance for AXA1665

Axcella decides not to expand enrollment in AXA4010-001 following cohort 1 readout

Is Axcella Health Inc.'s (NASDAQ:AXLA) Shareholder Ownership Skewed Towards Insiders?

New 90-day high: US$5.41

Axcella Health Inc. to Report Q3, 2020 Results on Nov 12, 2020

Price target lowered to US$14.43

New 90-day low: US$4.12

Price target lowered to US$17.60

Axcella Health Inc. to Report Q2, 2020 Results on Aug 05, 2020

Price target raised to US$19.40

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad